RENOLIT carves out healthcare market unit as independent company
RENOLIT Healthcare to be gradually spun off by the end of 2027
Worms, 5 December 2025 – The RENOLIT Group is setting the course for the future: the RENOLIT Healthcare market unit will be spun off from RENOLIT SE and gradually established as an independent company from 2026 onwards. With this strategic decision, RENOLIT is giving both divisions the opportunity to develop in a targeted manner. In future, RENOLIT SE will concentrate on its core industrial businesses, while RENOLIT Healthcare will focus entirely on the healthcare industry. Due to differences in markets, technologies and regulations, this specialisation is a logical step.
‘This decision provides clarity and focus,’ explains Karsten Jänicke, Chief Executive Officer of RENOLIT. ‘RENOLIT SE can continue to develop its core industrial markets in a targeted manner, while RENOLIT Healthcare positions itself as a specialist partner for the healthcare industry. This creates double growth potential.’
Andreas Lang, Chairman of the Supervisory Board and co-owner of RENOLIT, adds: ‘RENOLIT Healthcare is ready to go its own way. One thing is particularly important to us: as owners, we stand for continuity and stability. RENOLIT Healthcare will therefore remain part of the RENOLIT family, with all the values and culture that characterise us as a family owned business.’
Gradual carve-out by the end of 2027
The transition will take place in two phases. In 2026, the so-called virtual carve-out will begin, in which RENOLIT Healthcare will be managed independently in operational terms but will remain part of RENOLIT SE in legal terms. At the end of 2027, the legal spin-off into the new company RENOLIT Healthcare B.V., headquartered in the Netherlands, will follow. Until then, all decisions regarding the market units will remain within the remit of the current four-member Executive Board.
‘This is an extraordinary step,’ says Thomas Sampers, Executive Board Member of RENOLIT SE and designated Chief Executive Officer of RENOLIT Healthcare. ‘A family-owned business is investing in the future by giving a successful business division the freedom to operate independently. We are ready to go our own way – together with our customers, partners and employees.’
RENOLIT Healthcare is a leading provider of polymer solutions for applications in the healthcare industry. Among other things, the market unit produces materials for infusion, transfusion and dialysis systems as well as biotechnological applications. Under the motto ‘Together Towards Health’, RENOLIT Healthcare works with customers worldwide on innovations for a healthy future.
The company
The RENOLIT Group is a globally active specialist for high-quality plastic films, sheets and other polymer solutions. With more than thirty production sites and sales units in over twenty countries, and with annual sales of EUR 1.196 billion in fiscal year 2024, the company with headquarters in Worms – around 70 km south of Frankfurt-am-Main – is one of the world’s leading plastic products manufacturers. Around 5,000 employees continue to further develop the knowledge and expertise gained from seventy-five years of business.
